Committee for Advanced Therapies (CAT)

The main responsibility of the Committee for Advanced Therapies (CAT) is to prepare a draft opinion on each Advanced Therapy Medicinal Product (ATMP) application submitted to the European Medicines Agency (EMEA).

The CAT draft opinion is then forwarded to the Committee for Medicinal Products for Human Use (CHMP) adopts a final opinion on the granting, variation, suspension or revocation of a marketing authorisation for the medicine concerned. (ATMP Regulation 1394/2007)
 

  • Committee began in January 2009

 
Composition of Committee

  • 22 members from National Competent Authorities
  • 5 members from Committee for Human Medicinal Products (CHMP) + 5 alternates
  • 2 Health Care Professionals + 2 alternates
  • 2 Patients’ representatives + 2 alternates
  • 2 non-voting members (Iceland and Norway)

 
Fabrizia Bignami

Fabrizia Bignami is a Eurordis nominated Patient Representative
Current mandate: July 2009 – 2012
 
 
 
 
 
 
 
 
Michele Lipucci di PaolaMichele Lipucci di Paola is a Eurordis nominated Patient Representative
Current mandate: July 2009 – 2012
Thalassaemia Association Italy
 
 
 
 
 
 
 
 
Christian SchneiderChristian Schneider, Chairman of the CAT
 
 

Page created: 02/02/2010
Page last updated: 23/02/2010